ATEA PHARMACEUTICALS ($AVIR) posted quarterly earnings results for Q2 2026 on Wednesday, August 12th. The company reported earnings of -$0.41 per share, beating estimates of -$0.57 by $0.16. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $AVIR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ATEA PHARMACEUTICALS Hedge Fund Activity
We have seen 72 institutional investors add shares of ATEA PHARMACEUTICALS stock to their portfolio, and 44 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,271,776 shares (+23.5%) to their portfolio in Q1 2026, for an estimated $12,222,154
- ROSALIND ADVISORS, INC. added 1,171,855 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,304,579
- TWO SIGMA INVESTMENTS, LP added 1,118,749 shares (+150.1%) to their portfolio in Q1 2026, for an estimated $6,018,869
- JPMORGAN CHASE & CO added 945,918 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,398,518
- CURATED WEALTH PARTNERS LLC added 695,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,231,750
- MILLENNIUM MANAGEMENT LLC removed 348,224 shares (-49.9%) from their portfolio in Q1 2026, for an estimated $1,873,445
- IRENIC CAPITAL MANAGEMENT LP added 301,699 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,623,140
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
